Wedbush Has Optimistic View of Disc Medicine FY2026 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at Wedbush lifted their FY2026 earnings estimates for shares of Disc Medicine in a research note issued on Tuesday, January 21st. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($3.96) for the year, up from their prior forecast of ($4.19). Wedbush currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s FY2027 earnings at $2.64 EPS.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15.

Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus increased their price objective on shares of Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Scotiabank raised their price target on shares of Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $118.00 price target on shares of Disc Medicine in a research note on Tuesday. Finally, Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target on the stock in a research note on Tuesday, November 5th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $88.50.

Disc Medicine Trading Down 2.6 %

Shares of NASDAQ IRON opened at $56.99 on Thursday. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -14.32 and a beta of 0.75. Disc Medicine has a 52 week low of $25.60 and a 52 week high of $77.60. The company’s 50-day moving average price is $62.66 and its 200 day moving average price is $53.72.

Insider Buying and Selling

In related news, CEO John D. Quisel sold 12,791 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $66.01, for a total value of $844,333.91. Following the transaction, the chief executive officer now owns 72,065 shares in the company, valued at approximately $4,757,010.65. This trade represents a 15.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Rahul Khara sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total transaction of $470,625.00. Following the completion of the transaction, the insider now owns 14,035 shares in the company, valued at $880,696.25. The trade was a 34.83 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,758 shares of company stock valued at $5,400,990. Insiders own 4.24% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IRON. Amalgamated Bank raised its holdings in Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after buying an additional 247 shares during the period. Marshall Wace LLP purchased a new position in Disc Medicine in the second quarter valued at approximately $554,000. Point72 Asset Management L.P. purchased a new position in Disc Medicine in the second quarter valued at approximately $34,318,000. Deerfield Management Company L.P. Series C raised its holdings in Disc Medicine by 53.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after buying an additional 357,730 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Disc Medicine by 26.7% during the second quarter. The Manufacturers Life Insurance Company now owns 28,294 shares of the company’s stock valued at $1,275,000 after purchasing an additional 5,960 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.